Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HTG Molecular Diagnostics has formed a research collaboration agreement with Bristol-Myers Squibb to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types.
Subscribe to our email newsletter
The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational research activities.
HTG chief business officer John Lubniewski said: "We believe this collaboration will provide many benefits to Bristol-Myers Squibb’s immuno-oncology development programs and further add to HTG’s industry leadership in the development of NGS-based molecular diagnostic assays toward the goal of precision medicine.
"This collaboration is the result of a long-standing Bristol-Myers Squibb/HTG relationship and we are excited to continue as a partner with Bristol-Myers Squibb’s translational research team.
Under the terms of the agreement, HTG will provide Bristol-Myers Squibb access to its NGS-based HTG EdgeSeq system and the companies will collaborate to develop tools for use for molecular profiling research for immuno-oncology.
"Immuno-oncology is a very important business segment for us and this agreement and the expansion of our relationship with BMS is a validation of our HTG EdgeSeq technology and value proposition," stated TJ Johnson, President and CEO of HTG Molecular Diagnostics.
"We firmly believe in the potential of immuno therapies in treating cancer patients and we are honored to be chosen as a profiling partner for Bristol-Myers Squibb, a recognized leader in this space."